Halozyme Therapeutics (HALO) reported Q1 non-GAAP earnings Tuesday of $1.11 per diluted share, up compared with $0.79 a year earlier.

Analysts polled by FactSet expected $0.92.

Revenue for the quarter ended March 31 was $264.9 million, up compared with $195.6 million a year earlier.

Analysts expected $230.1 million.

For 2025, the biopharmaceutical company is now projecting adjusted EPS of $5.30 to $5.70 on revenue of $1.20 billion to $1.28 billion, up from its prior forecast expecting $4.95 to $5.35 per share on revenue of $1.15 billion to $1.23 billion.

Analysts are looking for $5.09 and $1.2 billion, respectively.

Halozyme also said it has authorized a second $250 million stock buyback program as part of its broader $750 million share repurchase plan disclosed in February 2024.

Halozyme shares were more than 6% higher in recent after-hours activity.